Academisch Ziekenhuis Leiden

Treatment & access

• Treatments offeredEsketamine nasal spray (Spravato®)
• Access routeTrial
• Cost & coverage (registry status)Free within clinical trial
• Websitehttps://www.lumc.nl

Related listings

These records belong to the same organisation. They are listed separately because each is a distinct programme or location.

• Another programme at this clinicLeiden University Medical Center : Clinical trials
• Another programme at this clinicLeiden University Medical Center (LUMC) : Clinical trials

About this provider

Compiled from the registry data on this page.

The EU Clinical Trials Information System (CTIS) records Academisch Ziekenhuis Leiden in Leiden, Netherlands, as a site of trial 2023-508125-27-00: an open-label pilot trial of esketamine nasal spray (Spravato) for therapy-resistant bipolar depression, sponsored by Academisch Ziekenhuis Leiden. This directory lists the site for esketamine (Spravato); access is through participation in the trial, and treatment is free within the clinical trial. The CTIS public record is the registry source cited by this entry. The record was last verified on 2026-07-29.

13 more verified providers within 50 km

• Alphen aan den Rijn · 11 kmSanctuary Kliniek : Spravato®
• Den Haag · 15 kmPsyQ : Spravato®
• Delft · 20 kmGGZ Delfland : Spravato®

See them on the provider map →

What to prepare before you enquire

• A referral or the contact details of your treating clinician
• A list of medications you have tried (names, doses, duration)
• A short diagnosis summary or discharge letters

The research team confirms eligibility against your medical records at a screening visit.

Send documents directly to the provider when they reply. We never ask you to upload medical records.